Migraine Therapeutics Differentially Modulate the CGRP Pathway

Overview

Journal Cephalalgia

Specialties Neurology
Psychiatry

Date 2021 Feb 25

PMID 33626922

Citations 46

Authors

Minoti Bhakta

Trang Vuong

Tetsuya Taura

David S Wilson

Jennifer R Stratton

Kimberly D Mackenzie

Affiliations

Soon will be listed here.

Abstract

Background: The clinical efficacy of migraine therapeutic agents directed towards the calcitonin-gene related peptide (CGRP) pathway has confirmed the key role of this axis in migraine pathogenesis. Three antibodies against CGRP - fremanezumab, galcanezumab and eptinezumab - and one antibody against the CGRP receptor, erenumab, are clinically approved therapeutics for the prevention of migraine. In addition, two small molecule CGRP receptor antagonists, ubrogepant and rimegepant, are approved for acute migraine treatment. Targeting either the CGRP ligand or receptor is efficacious for migraine treatment; however, a comparison of the mechanism of action of these therapeutic agents is lacking in the literature.

Methods: To gain insights into the potential differences between these CGRP pathway therapeutics, we compared the effect of a CGRP ligand antibody (fremanezumab), a CGRP receptor antibody (erenumab) and a CGRP receptor small molecule antagonist (telcagepant) using a combination of binding, functional and imaging assays.

Results: Erenumab and telcagepant antagonized CGRP, adrenomedullin and intermedin cAMP signaling at the canonical human CGRP receptor. In contrast, fremanezumab only antagonized CGRP-induced cAMP signaling at the human CGRP receptor. In addition, erenumab, but not fremanezumab, bound and internalized at the canonical human CGRP receptor. Interestingly, erenumab also bound and internalized at the human AMY receptor, a CGRP receptor family member. Both erenumab and telcagepant antagonized amylin-induced cAMP signaling at the AMY receptor while fremanezumab did not affect amylin responses.

Conclusion: The therapeutic effect of agents targeting the CGRP ligand versus receptor for migraine prevention (antibodies) or acute treatment (gepants) may involve distinct mechanisms of action. These findings suggest that differing mechanisms could affect efficacy, safety, and/or tolerability in migraine patients.

Citing Articles

Shared Genetics of Migraine and Gastrointestinal Disorders Implicates Underlying Neurologic Mechanisms Yet Heterogeneous Etiologies.

Chasman D, Guo Y, Chan A, Rist P, Staller K Neurol Genet. 2024; 10(6):e200201.

PMID: 39677849 PMC: 11637577. DOI: 10.1212/NXG.0000000000200201.

Combining treatments for migraine prophylaxis: the state-of-the-art.

Pellesi L, Garcia-Azorin D, Rubio-Beltran E, Ha W, Messina R, Ornello R J Headache Pain. 2024; 25(1):214.

PMID: 39639191 PMC: 11619619. DOI: 10.1186/s10194-024-01925-w.

Switching from ligand to receptor anti-calcitonin gene-related peptide (CGRP) antibodies or vice versa in non-responders: A controlled cohort study.

van Veelen N, van der Arend B, Hiele E, van Zwet E, Terwindt G Eur J Neurol. 2024; 32(1):e16542.

PMID: 39607215 PMC: 11625943. DOI: 10.1111/ene.16542.

Novel Calcitonin Gene-Related Peptide (CGRP) Interfering Migraine Therapies and Stroke-A Review.

Eller M, Frank F, Kaltseis K, Karisik A, Knoflach M, Broessner G Int J Mol Sci. 2024; 25(21).

PMID: 39519240 PMC: 11546425. DOI: 10.3390/ijms252111685.

Differential expression of components of the CGRP-receptor family in human coronary and human middle meningeal arteries: functional implications.

de Vries T, Schutter D, van den Bogaerdt A, Vincent A, Dammers R, Danser A J Headache Pain. 2024; 25(1):176.

PMID: 39390360 PMC: 11465939. DOI: 10.1186/s10194-024-01863-7.

References

Moore E, Fraley M, Bell I, Burgey C, White R, Li C . Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor. J Pharmacol Exp Ther. 2020; 373(1). DOI: 10.1124/jpet.119.261065. View

McLatchie L, Fraser N, Main M, Wise A, Brown J, Thompson N . RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998; 393(6683):333-9. DOI: 10.1038/30666. View

Zhang S, Xu M, Wang X . Adrenomedullin 2/intermedin: a putative drug candidate for treatment of cardiometabolic diseases. Br J Pharmacol. 2017; 175(8):1230-1240. PMC: 5867024. DOI: 10.1111/bph.13814. View

Shi L, Lehto S, Zhu D, Sun H, Zhang J, Smith B . Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor. J Pharmacol Exp Ther. 2015; 356(1):223-31. DOI: 10.1124/jpet.115.227793. View

Poyner D, Sexton P, Marshall I, Smith D, Quirion R, Born W . International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002; 54(2):233-46. DOI: 10.1124/pr.54.2.233. View

Walker C, Raddant A, Woolley M, Russo A, Hay D . CGRP receptor antagonist activity of olcegepant depends on the signalling pathway measured. Cephalalgia. 2017; 38(3):437-451. PMC: 5494006. DOI: 10.1177/0333102417691762. View

Pioszak A, Hay D . RAMPs as allosteric modulators of the calcitonin and calcitonin-like class B G protein-coupled receptors. Adv Pharmacol. 2020; 88:115-141. PMC: 7374980. DOI: 10.1016/bs.apha.2020.01.001. View

Hay D, Garelja M, Poyner D, Walker C . Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. Br J Pharmacol. 2017; 175(1):3-17. PMC: 5740251. DOI: 10.1111/bph.14075. View

Wong H, Cheung T, Cheung B . Adrenomedullin and cardiovascular diseases. JRSM Cardiovasc Dis. 2013; 1(5). PMC: 3738363. DOI: 10.1258/cvd.2012.012003. View

10.

Padilla B, Cottrell G, Roosterman D, Pikios S, Muller L, Steinhoff M . Endothelin-converting enzyme-1 regulates endosomal sorting of calcitonin receptor-like receptor and beta-arrestins. J Cell Biol. 2007; 179(5):981-97. PMC: 2099187. DOI: 10.1083/jcb.200704053. View

11.

Mallee J, Salvatore C, LeBourdelles B, Oliver K, Longmore J, Koblan K . Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem. 2002; 277(16):14294-8. DOI: 10.1074/jbc.M109661200. View

12.

Cottrell G . CGRP Receptor Signalling Pathways. Handb Exp Pharmacol. 2018; 255:37-64. DOI: 10.1007/164_2018_130. View

13.

Manoukian R, Sun H, Miller S, Shi D, Chan B, Xu C . Effects of monoclonal antagonist antibodies on calcitonin gene-related peptide receptor function and trafficking. J Headache Pain. 2019; 20(1):44. PMC: 6734291. DOI: 10.1186/s10194-019-0992-1. View

14.

Yarwood R, Imlach W, Lieu T, Veldhuis N, Jensen D, Klein Herenbrink C . Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission. Proc Natl Acad Sci U S A. 2017; 114(46):12309-12314. PMC: 5699040. DOI: 10.1073/pnas.1706656114. View

15.

Pan K, Siow A, Hay D, Walker C . Antagonism of CGRP Signaling by Rimegepant at Two Receptors. Front Pharmacol. 2020; 11:1240. PMC: 7468408. DOI: 10.3389/fphar.2020.01240. View

16.

Moore E, Salvatore C . Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine. Br J Pharmacol. 2011; 166(1):66-78. PMC: 3415638. DOI: 10.1111/j.1476-5381.2011.01633.x. View

17.

Liang Y, Khoshouei M, Deganutti G, Glukhova A, Koole C, Peat T . Cryo-EM structure of the active, G-protein complexed, human CGRP receptor. Nature. 2018; 561(7724):492-497. PMC: 6166790. DOI: 10.1038/s41586-018-0535-y. View

18.

Do T, Guo S, Ashina M . Therapeutic novelties in migraine: new drugs, new hope?. J Headache Pain. 2019; 20(1):37. PMC: 6734360. DOI: 10.1186/s10194-019-0974-3. View

19.

Ter Haar E, Koth C, Abdul-Manan N, Swenson L, Coll J, Lippke J . Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. Structure. 2010; 18(9):1083-93. DOI: 10.1016/j.str.2010.05.014. View

20.

Bussiere J, Davies R, Dean C, Xu C, Kim K, Vargas H . Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine. Regul Toxicol Pharmacol. 2019; 106:224-238. DOI: 10.1016/j.yrtph.2019.05.013. View